Replies to post #110334 on Biotech Values

[DewDiligence]

…the timing doesn't sit well with me. one would think the stock in 6 months without another generic approved would have to be 20% higher. then again from a big picture standpoint waiting 6 months to move the business forward to try and get 20% more for a modest sized offering, while taking even a small chance that teva gets approved and potentially killing any equity financing at a palatable price may have been what management was weighing.

I think the risk of a bear market for stocks in general was a bigger factor in the timing of MNTA’s financing than concerns about Teva’s Lovenox.

[HattieTheWitch]

Teva Can Hurdle a Wall of Worry

http://online.barrons.com/article/SB50001424052970203293704576005973910084628.html?mod=BOL_twm_da

"WITH GENERIC DRUGS PLAYING such a big role in efforts in the U.S. and abroad to cut health-care costs, Teva Pharmaceutical Industries is sitting pretty.

It's the world's largest maker of low-priced versions of branded-prescription medications, dominating a $93 billion generic-drug industry that could almost double in size by 2015.

Too bad investors don't seem to care – at least now.

At less than $49 a share, Teva's American depositary receipts (ticker: TEVA) have fallen 25% off a record-high close in March amid worries about future earnings growth and the fate of its top-selling multiple sclerosis drug Copaxone, which happens to be a branded product..."